Paraskevas GP, et al. - Using double-sandwich commercial ELISAs (Innotest; Fujirebio, Gent, Belgium), researchers measured cerebrospinal fluid (CSF) levels of β-amyloid peptide with 42 amino acids (Aβ42), total tau protein (τT), and tau phosphorylated at threonine 181 (τP-181) in 38 patients satisfying the diagnostic criteria for probable dementia with Lewy bodies (DLB). According to current cut-off values, four biomarker profiles were observed: abnormal levels of Aβ42 only (44.7%), full Alzheimer’s disease (AD) profile (39.5%), abnormal levels of τT only (5.3%), and normal levels of all three biomarkers (10.5%). Findings suggested an association of AD profile with female sex, older age, lower education, and lower MMSE scores. According to results, decrease in Αβ42 in DLB may be more prevalent (>80% of patients) than earlier assumed, and ∼40% may have the typical CSF AD biomarker profile. AD biochemistry in DLB may be a developing process that shows growing frequency with progression of the disease.